Yukihiro Chino

Nov 1, 2023 | accp1.onlinelibrary.wiley.com | Tsutomu Takeuchi |Taisho Pharmaceutical Co |Ltd. Osaka Japan |Yukihiro Chino

Ozoralizumab is a bispecific NANOBODY® compound that binds tumor necrosis factor alpha (TNFα) and human serum albumin (HSA). Ozoralizumab inhibits the TNFα physiological activity while maintaining long-term plasma retention owing to its HSA-binding ability. A population pharmacokinetic (PK) model was developed using data from 494 Japanese patients with rheumatoid arthritis (RA) in phase II/III and phase III trials to assess the effects of potential PK covariates.